Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Novartis’ Zykadia ASCEND-4 Study Close But No Cigar In NSCLC

Executive Summary

The presentation of the full data from Novartis’ ASCEND-4 study of Zykadia show decent efficacy in first-line NSCLC but are unlikely to be enough to overcome doctors’ caution over its tolerability profile, especially with rival Alecensa snapping at its heels.

You may also be interested in...



Brain Benefits Boost Roche's Alecensa In ALK Lung Cancer Race

Data from two studies confirm Alecensa's superiority over Pfizer's Xalkori and help Roche close the gap on Novartis' Zykadia.

Keeping Track: A Blizzard Of Submissions And A Small Flurry Of Approvals

The latest drug development news and highlights from our US FDA Performance Tracker.

Zykadia Challenged As Roche’s Alecensa Gets EU Nod

Roche’s Alecensa gets EU nod for second-line use in ALK+ non-small cell lung cancer patients – but first-line data in 2017 will be vital.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

SC097824

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel